

Cover Story
Guest Editorial
At a recent NIH study section that I chaired, we had many applications that we reviewed as a group before the meeting. At the meeting, we were required to discuss over 50% of the grants.
By Claire Dietz and Matthew Bin Han Ong
Conversation with The Cancer Letter
By Matthew Bin Han Ong and Claire Dietz
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
NCI Trials


NCI Trials for July
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
- John Burklow replaced by Seana Cranston as NIH chief of staff
















